{"preliminary_commentary":{"by_channel":{"x_thread":35,"youtube":1,"podcast":1,"bluesky_thread":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05814354\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"HORIZON-Breast06","nct_id":"NCT05814354","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=horizon-breast06-nct05814354. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"SHR-A1811","type":"EXPERIMENTAL"},{"description":"Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel","label":"Physician's Choice","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-06-30","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":551,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"SHR-A1811","otherNames":[],"type":"DRUG"},{"name":"Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-06","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","official_title":"A Randomized, Open, Parallel-controlled, Multicenter Phase III Trial of SHR-A1811 Versus Investigator Chemotherapy in HER2-low Expressing Recurrent/Metastatic Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-03-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) Based on Blind Independent Video Review Committee (BIRC)","timeFrame":"within approximately 2 years"}],"references":[{"citation":"Fan Y, Liu Y, Wang Y, Ouyang Q, Zhang Q, Cui J, Li J, Ding Q, Wu X, Wang X, Tong Z, Zeng Y, Wang W, Yan M, Wang Y, Liu X, Li K, Sun Z, Yuan C, Wang T, Xie W, Yao J, Zhou S, Hou J, Ouyang Z, Li Y, Cui S, Zhang X, Zhu X, Xu B. Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial. JAMA. 2026 Oct 23:e2621372. doi: 10.1001/jama.2026.21372. Online ahead of print.","pmid":"42925007","type":"DERIVED"}],"start_date":{"date":"2023-06-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","url":"https://clinicaltrials.gov/study/NCT05814354"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/horizon-breast06-nct05814354"}